Table 4.
Examples of new molecular entities targeting protein kinases C (PKCs). FLT3: Fms-like tyrosine kinase 3; cPKCs: classical/conventional PKCs; nPKCs: novel PKCs.
| Drug | Nature of Effect | Targeted PKC(s) | Putative Therapeutic Indication |
|---|---|---|---|
| Rubixostaurin | PKC inhibition | PKCβ | Microvascular complications of diabetes [163,164] |
| Enzastaurin | PKC inhibition | PKCβ | Cancers [165] |
| Tamoxifen | PKC inhibition | Pan-PKC | Bipolar disorders [166] |
| Sotrastaurin (AEB071) | PKC inhibition | Pan-PKC | Organ transplantation [167], psoriasis [168] |
| KAI-9803 | PKC inhibition | PKCδ | Coronary intervention for myocardial infarction [169] |
| Midostaurin | PKC/FLT3/multikinase inhibition | Pan-PKC | Leukemias [170] |
| Ingenol mebutate | PKC activation | cPKCs/nPKCs | Actinic keratoses [171] |